Jakarta. Singapore-based health tech startup, Mesh Bio, has raised $3.5 million (Rp 55.29 billion) in a Series A financing round led by East Ventures and participated by Elev8, Seed Capitals, and other existing shareholders.

The funds will enable Mesh Bio to extend its digital twin technologies to healthcare providers and expand the deployment of these solutions across Hong Kong and Southeast Asia, with a particular focus on Indonesia and the Philippines.

Digital twin technology refers to a virtual representation of a physical object, created using real-time data from the physical entity, allowing for a dynamic and up-to-date model. 

In October 2023, the company received approval from Singapore’s Health Sciences Authority (HSA) to market its HealthVector Diabetes as a software medical device (SaMD). Currently, HealthVector Diabetes is undergoing an implementation pilot at Singapore General Hospital (SGH), Tan Tock Seng Hospital (TTSH), and selected polyclinics for potential clinical adoption.

“We are excited to announce the closure of our Series A funding, this pivotal step empowers us to expand our digital health solutions for chronic disease management in Southeast Asia. The region presents myriad unmet healthcare needs, and our focus is to address these gaps effectively," Andrew Wu, Co-Founder and Chief Executive Officer of Mesh Bio, said on Tuesday.

Mesh Bio's app has been utilized by over 120 medical centers across Singapore, Malaysia, and Indonesia for preventive health screening.

Founded in 2018, Mesh Bio had previously raised $1.8 million in a seed funding round in October 2021.